Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

CytomX Therapeutics, Inc. CTMX

Healthcare  —  Biotechnology
2.70 (0.05) (1.82%) as of 25 Sep
Market cap
$599.2M
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K
Quarterly (Descending) Quarterly (Ascending) Annual (Descending) Annual (Ascending) TTM (Descending) TTM (Ascending)
Download Excel — free account

A Cash Flow Statement is a financial report that details the cash inflows and outflows of a company over a specific period. It is divided into three sections: operating activities, investing activities, and financing activities. This statement helps assess the company’s liquidity, solvency, and overall financial health. By tracking cash movements, it provides insights into the company's ability to generate cash to fund operations, pay debts, and invest in growth. Businesses and investors use it to evaluate the sustainability of a company's cash flow and its financial stability.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Net Income (17.37) 31.87 (0.57) (99.32) (115.87) (32.88) (102.24) (84.60) (43.10) (58.90)
Depreciation & Amortization (0.83) (3.54) (5.24) 2.39 2.98 2.34 0.38 0.18 2.03 3.40
Non Cash Items (Other) 11.19 11.86 12.29 16.79 16.30 17.67 23.37 16.88 21.47 10.21
Accounts Receivable Change 1.09 0.33 32.55 (35.20) 0.01 (0.78) 0.08 10.04 (7.83) (1.57)
Accounts Payable Change 0.22 (0.30) (1.43) 0.07 (0.14) (0.86) (0.37) 0.26 (2.44) 1.77
Change in payables and accrued liability (3.05) (9.63) (7.04) (9.78) 7.56 (11.04) (15.40) 24.83 9.16 3.95
Change in other assets and liabilities (66.84) (116.82) (86.60) 14.26 (29.87) 30.82 (46.31) (43.11) 191.08 39.11
Operating Cash Flow (75.59) (86.23) (56.03) (110.79) (119.03) 5.26 (140.48) (75.52) 170.37 (2.03)
Capital expenditures (0.22) (0.31) (0.84) (1.74) (1.61) (2.31) (3.50) (3.79) (1.56) (2.12)
Short Term Investments Change (Net) (59.52) 100.01 (149.83) 100.00 24.10 (16.41) 83.20 9.71 (119.71) 47.98
Investing cash flow (59.74) 99.70 (150.67) 98.26 22.49 (18.72) 79.70 5.93 (121.27) 45.86
Repayment/Issuance of Debt (Net) — — — — — — — — — 0.07
Equity Repurchase (Common, Net) 110.45 7.52 30.23 0.65 110.21 16.89 1.63 139.62 23.80 0.93
Other financial activities — — — 13.33 13.44 14.55 18.47 15.18 22.38 0.07
Financing cash flow 110.45 7.52 30.23 0.65 110.21 16.89 1.63 139.62 23.80 1.00
Change in Cash (24.88) 20.99 (176.48) (11.88) 13.67 3.43 (59.15) 70.03 72.90 44.82
Beginning Cash 39.08 18.09 194.57 206.45 192.78 189.34 248.49 178.47 105.56 60.74
Ending Cash 14.19 39.08 18.09 194.57 206.45 192.78 189.34 248.49 178.47 105.56
Stock Based Compensation 6.30 7.67 8.56 13.13 13.17 14.79 19.10 16.88 11.29 10.10
Dividends Paid (Common) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Cash/Marketcap 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Assets Liabilities Change (Total) (68.58) (126.41) (62.51) (30.65) (22.44) 18.13 (61.99) (7.98) 189.97 43.26
Investments Change (Net) (59.52) 100.01 (149.83) 100.00 24.10 (16.41) 83.20 9.71 (119.71) 47.98
Issuance/Purchase of Shares 110.45 7.52 30.23 0.65 110.21 16.89 1.63 139.62 23.80 0.93
Other line items
Revenue per Employee 1.10 1.14 0.83 0.45 0.21 0.69 0.36 0.43 0.77 0.19

Fold the line items

In millions of $ except per-share values · columns are period end dates